TuHURA Biosciences financials
$2.07−0.96%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 |
| Gross margin | — | — |
| Operating income | -$31.8M | -$17.6M |
| Net income | -$30.1M | -$22.6M |
| Net margin | — | — |
| Diluted EPS | $-0.63 | $-1.21 |
| EBITDA | -$28.0M | -$17.1M |
| Operating cash flow | -$27.6M | -$14.7M |
| Free cash flow | -$27.7M | -$14.8M |
| Diluted shares | 47.9M | 18.7M |
Balance sheet
| Period end | Dec 31 | Dec 31 |
|---|---|---|
| Cash & equivalents | $3.6M | $12.7M |
| Short-term investments | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 |
| Total assets | $27.4M | $20.0M |
| Total liabilities | $6.4M | $5.4M |
| Shareholders' equity | $20.9M | $14.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology